

Nasal drugs show promise for slowing Parkinson's disease progression in lab study

September 21 2021



Immunohistochemistry for alpha-synuclein showing positive staining (brown) of an intraneural Lewy-body in the Substantia nigra in Parkinson's disease. Credit: Wikipedia

Potential new treatments for Parkinson's disease developed by

researchers at Rush University Medical Center have shown success in slowing progression of the disease in mice.

In a study published in *Nature Communications*, Rush researchers found that two different peptides (chains of amino acids) helped slow the spread of alpha-synuclein, a protein that occurs in abnormal protein deposits called Lewy bodies in the brain. Lewy bodies are hallmarks of Parkinson's [disease](#), the most common movement disorder affecting about 1.2 million people in the United States and Canada.

"Currently, there are no treatments that slow the progression of Parkinson's disease—they only treat the symptoms," says Kalipada Pahan, Ph.D., the Floyd A. Davis Professor of Neurology at Rush University Medical Center and a research career scientist at the Jesse Brown VA Medical Center, who led the study.

Lewy bodies are also associated with the development of Lewy body dementia and a rare neurological disorder called multiple system atrophy (MSA). "At present, there is also no [effective treatment](#) for dementia with Lewy bodies and multiple system atrophy," Pahan says.

"Understanding how these diseases work is important to developing effective drugs that inhibit alpha-synuclein pathology, protect the brain, and stop the progression of Lewy [body](#) diseases."

The lab-developed peptides tested in the study are known as TLR2-interacting domain of Myd88 (TIDM) and NEMO-binding domain (NBD). The drugs, which were delivered through the nose, were found to slow inflammation in the brain and stop the spread of alpha-synuclein in mice with Parkinson's disease. The treatments also improved the mice's gait, balance, and other motor functions.

"If these results can be replicated in patients, it would be a remarkable advance in the treatment of devastating neurological disorders," Pahan

says.

The research was supported by funding from the National Institutes of Health. Other authors of the article are Debashis Dutta, Ph.D.; Malabendu Jana, Ph.D.; Moumita Majumder, Ph.D.; Susanta Mondal, Ph.D.; and Avik Roy, Ph.D., all from Rush University Medical Center.

More information: Debashis Dutta et al, Selective targeting of the TLR2/MyD88/NF- κ B pathway reduces α -synuclein spreading in vitro and in vivo, *Nature Communications* (2021). [DOI: 10.1038/s41467-021-25767-1](https://doi.org/10.1038/s41467-021-25767-1)

Provided by Rush University Medical Center

Citation: Nasal drugs show promise for slowing Parkinson's disease progression in lab study (2021, September 21) retrieved 27 April 2024 from <https://medicalxpress.com/news/2021-09-nasal-drugs-parkinson-disease-lab.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.